| Autor: |
Gutierrez M; Department of Gastroenterology, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA., Kesavan C; Department of Gastroenterology, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA.; Department of Medicine, Loma Linda University, Loma Linda, CA 92357, USA.; Musculoskeletal Disease Center, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA., Das A; Department of Gastroenterology, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA., Jackson CS; Department of Gastroenterology, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA.; Department of Medicine, Loma Linda University, Loma Linda, CA 92357, USA.; School of Medicine, University of California, Riverside, CA 92521, USA., Strong RM; Department of Gastroenterology, VA Loma Linda Veterans Healthcare System, Loma Linda, CA 92354, USA.; Department of Medicine, Loma Linda University, Loma Linda, CA 92357, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2023 Jan 31; Vol. 13 (3). Date of Electronic Publication: 2023 Jan 31. |
| DOI: |
10.3390/diagnostics13030525 |
| Abstrakt: |
Background: Gastrointestinal angiodysplasias (GIADs), also known as gastrointestinal angioectasias, are dilated, abnormally thin-walled blood vessels that occur in the mucosa and submucosa throughout the gastrointestinal tract. As a common cause of small bowel bleeding, GIADs have a significant impact on patient's morbidity and healthcare costs. Presently, somatostatin has been used widely to treat GIADs, but it is unclear if other therapies are as beneficial and cost-effective as somatostatin in managing GIADs. (2) Methods: A retrospective chart review was performed, which included subjects treated with Lanreotide, a somatostatin analog, and other therapies at the VA Loma Linda Healthcare System (VALLHCC) from January 2006 to December 2018. Patients who had symptomatic GIADs were detected by video capsule endoscopy (VCE), a device-assisted enteroscopy (DAE) or, in our case, push enteroscopy (PE) with an Endocuff. (3) Results: Three hundred twelve patients were diagnosed with GIADs. In this group of patients, 72 underwent ablation (endoscopic BICAP) with the addition of Lanreotide (SST), 63 underwent ablation therapy, eight were treated with SST only, 128 received iron replacement only, 25 received iron plus SST therapy, and 61 were observed with no therapy. Each group was followed via their hemoglobin (Hgb) level immediately thereafter, and Hgb levels were then obtained every 3 months for a 12-month period. After ablation therapy, 63 patients maintained stable Hgb levels over the course of the study, suggesting a significant therapeutic effect by controlling active bleeding. The 27 patients receiving ablation +SST therapy did not show improvements when compared to ablation only and the 128 patients who received iron therapy alone. (4) Conclusions: Importantly, 12 years of managing these patients has given us a cost- and time-sensitive strategy to maintain the patients' Hgb levels and avoid hospital admissions for acute bleeding. Iron treatment alone is effective compared to SST treatment in recovering from GIADs. Eliminating SST treatment from therapeutic intervention would save $89,100-445,550 per patient, depending on the number of doses for private care patients and $14,286-28,772 for VA patients, respectively. A suggested therapy would be to perform DAE on actively bleeding patients, ablate the lesions using a coagulation method, and place the patient on iron. If that fails, gastroenterologists should repeat VCE and perform either PE with Endocuff or balloon enteroscopy (all DAEs). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
